SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
Clinical trial NCT05398614 · UNKNOWN
Trial details
- NCT number
- NCT05398614
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-01
- Primary completion
- 2023-12-30
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.